All In Biotech

Drug Trial Radar · NCT06358872

Azithromycin for Child Survival in Niger II

Azithromycine Pour la Vie Des Enfants au Niger II

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 3,300,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

3,300,000

Planned (sponsor's estimate)

Start

Apr 29, 2024

Primary completion

Apr 29, 2028

Study completion Apr 29, 2028

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Centre de recherche et interventions en santé publique (CRISP); Ministère de la Santé Publique du Niger; Le Programme National de Santé Oculaire; Centre de Recherche Médicale et Sanitaire; Bill and Melinda Gates Foundation
First posted
Apr 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 59 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Several randomized controlled trials have demonstrated that azithromycin mass drug administration (MDA) reduces child mortality, but increases antimicrobial resistance (AMR). The World Health Organization (WHO) guidelines for this intervention specify that implementation must be accompanied by continued monitoring of mortality and AMR. Niger is expanding the azithromycin MDA program nationwide. To establish monitoring of mortality and AMR as part of this program as well as to leverage the infrastructure to evaluate other child health interventions, AVENIR II is designed as an adaptive platform trial with monitoring and re-randomization every 2 years.

Conditions

  • Mortality
  • Antimicrobial Resistance

Interventions

  • Azithromycin for Oral SuspensionDrug

    Azithromycin will be administered as a single dose, in oral suspension form for children. The dose will be calculated by age or height depending on the child's age Both dosing cups and syringes will be used to administer treatment. For children too young to drink out of a dosing cup, a 1 ml or 5 ml syringe will be used, and the calculated dose will be rounded upwards to the nearest 0.2 ml.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortalityTime frame: 2 years
  2. All-cause mortalityTime frame: 4 years
  3. Prevalence of resistance to macrolides - nasopharyngeal swabsTime frame: 2 years
  4. Prevalence of resistance to macrolides - nasopharyngeal swabsTime frame: 4 years
  5. Load of genetic determinants of resistance to macrolides - rectal swabsTime frame: 2 years
  6. Load of genetic determinants of resistance to macrolides - rectal swabsTime frame: 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Program National de Santé Oculaire

    Niamey, Niger · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.